ABSTRACT
Diurnal variation in biofluid metabolome as observed in a healthy human may alter in perturbed conditions. Biofluids like urine are rich in molecular constituents including metabolites, and infectious disease conditions like tuberculosis (TB) may influence diurnal differences for which limited reports are available in the literature. In this study, we present an optimized gas chromatography coupled to a quadrupole mass spectrometry (GC-MS) method to analyze processed and trimethylsilyl (TMS) derivatized urine metabolites. Urine samples were collected at four time points (0, 6, 12 and 24 hours) of study subjects [n=15; mean age 37 (24-70) in years] including controls [n=7; mean age 29.3 (24-35) years] and culture-confirmed active TB patients [ATB; n=8; mean age 43.7 (25-70) years] receiving treatment in the intensive phase. Global urine metabolite profiling was carried out using the optimized GC-MS method. Higher urine analyte diversity was observed in ATB patients (74) than in controls (36) during the day. Diurnal variations of the parent anti-TB drugs and their breakdown products (pyrazinamide, pyrazinoic acid, 5-hydroxy pyrazinoic acid, isonicotinic acid and alpha amino butyric acid) were observed with maximum abundance at 6 h. Interestingly, urine of ATB subjects at 6 h showed the highest metabolic diversity, whereas it was at 12 h in controls. Many analytes including glycine and alanine amino-acids showed diurnal variation in ATB and controls. These changes could be attributed to the altered host metabolic activities due to disease, treatment-associated decrease in total body bacterial burden and gut microbiota dysbiosis. And the optimized spiked-in internal standard, urine sample volume and GC-MS method could be used for global urine metabolome analysis in healthy and different perturbed conditions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is a clinical research project.
Funding Statement
We would like to acknowledge the contribution of all the hospital staffs at clinical sites involved in tuberculosis patient management and recruitment. Funding: Funding for this work was provided by the Department of Biotechnology (MDR-TB/2017/39), Government of India, as a research grant to RKN, DG, RH, SH, HLS. The core support from International Centre for Genetic Engineering and Biotechnology, New Delhi to RKN is highly acknowledged. FH has an Arturo Falaschi Fellowship support from ICGEB, Trieste, Italy. FP is supported by the fellowship from Department of Biotechnology, Government of India. SC is a Shyama Prasad Mukherjee fellow and is supported by Council of Scientific and Industrial Research, Government of India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed in accordance with the protocol approved from the Institutional Ethics Committee of Jawaharlal Nehru Institute of Medical Sciences (JNIMS), Imphal (Ref No. Ac/04/IEC/JNIMS/2017); Manipur University, Imphal (Ref No. Ac/IHEC/MU/003/2017) and International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi (Ref No. ICGEB/IEC/2018/06).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All mass spectrometry data files, used in this report, will be available to users by sending an email to the corresponding author.
